Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ABBV-706 versus standard of care in relapsed/refractory small cell lung cancer
jRCT2071250130Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing ABBV-706 with Standard of Care (2 arms). Primary endpoints: Objective response rate and Overall survival. Started May 2026; status: recruiting.
02
Drugs
turmetabart adizutecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071250130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250130.